HUMDF (Hua Medicine) Debt-to-Equity : -2.22 (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Hua Medicine Debt-to-Equity?

Hua Medicine's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $15.87 Mil. Hua Medicine's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $25.36 Mil. Hua Medicine's Total Stockholders Equity for the quarter that ended in Dec. 2024 was $-18.61 Mil. Hua Medicine's debt to equity for the quarter that ended in Dec. 2024 was -2.22.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Hua Medicine's Debt-to-Equity or its related term are showing as below:

HUMDF' s Debt-to-Equity Range Over the Past 10 Years
Min: -2.22 Med: 0.13 Max: 1.66
Current: -2.22

During the past 9 years, the highest Debt-to-Equity Ratio of Hua Medicine was 1.66. The lowest was -2.22. And the median was 0.13.

HUMDF's Debt-to-Equity is not ranked
in the Drug Manufacturers industry.
Industry Median: 0.28 vs HUMDF: -2.22

Hua Medicine Debt-to-Equity Historical Data

The historical data trend for Hua Medicine's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hua Medicine Debt-to-Equity Chart

Hua Medicine Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Equity

Get a 7-Day Free Trial

0.11

0.16

0.35

1.66

-2.22

Hua Medicine Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Debt-to-Equity	Get a 7-Day Free Trial												0.35	1.04	1.66	-8.21	-2.22

Competitive Comparison of Hua Medicine's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Hua Medicine's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hua Medicine's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hua Medicine's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Hua Medicine's Debt-to-Equity falls into.

Save Embed

;

Save Embed

;

Hua Medicine Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Hua Medicine's Debt to Equity Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(15.869	+	25.36)	/	-18.606
	=	-2.22

Hua Medicine's Debt to Equity Ratio for the quarter that ended in Dec. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(15.869	+	25.36)	/	-18.606
	=	-2.22

Hua Medicine (OTCPK:HUMDF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Hua Medicine Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Hua Medicine's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Hua Medicine Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hua Medicine (OTCPK:HUMDF) » Definitions » Debt-to-Equity

Traded in Other Exchanges

02552:Hong Kong

Address

Lane 36, Xuelin Road, Hua Medicine, Building 2, Pudong New Area, Shanghai, CHN, 201203

Website

https://www.huamedicine.com

Hua Medicine is an investment holding company. It is engaged in the development and commercialization of a first-in-class oral drug, Dorzagliatin or HMS5552, for the treatment of Type 2 diabetes. The group majorly operates in the PRC.